The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
-
Further examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.
-
Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.
-
Magnum XXL capsules pose a serious risk to your health and should not be taken.
-
Nitrosamine and Nitroso-structure impurities acceptable intakes update
We are updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI) -
Consent relating to listed medicines that contain whole live microorganisms as an active ingredient
This consent is given under sections 14 and 14A of the Therapeutic Goods Act 1989. -
Recall reforms update and new procedure
Recall reforms program update and preview of the PRAC Version 1.0.
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
This plan outlines our compliance and education priorities for 2024-2025.
-
This fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.